Ajay Kotagiri

Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

Jeffrey S. Heier, Eleonora M. Lad, Frank G. Holz et al. · The Lancet · 2023 · 372 citations

Ocular Disease, Ophthalmology, Age-related Diseases +4

Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial

Andrew Lotery, Sobha Sivaprasad, Abby O’Connell et al. · The Lancet · 2020 · 218 citations · Full text

Visual impairment, severe visual impairment, and blindness in children in Britain (BCVIS2): a national observational study

Lucinda Teoh, Ameenat Lola Solebo, Jugnoo S. Rahi et al. · The Lancet Child & Adolescent Health · 2021 · 67 citations · Full text

Ophthalmology, National Observational Study, Medicine +5

Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration

Adam H. Ross, Louise Downey, Helen Devonport et al. · Eye · 2020 · 65 citations · Full text

Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab

Raffaele Raimondi, Tina Falfeli, Anna Bogdanova-Bennet et al. · Ophthalmology Retina · 2023 · 52 citations

Ocular Disease, Ophthalmology, Age-related Diseases +4